GlobeNewswire by notified

Adevinta ASA (ADE) - Adevinta appoints Antoine Jouteau as Chief Executive Officer

Share

Oslo and Paris, 21 July 2022 - Adevinta ASA (ADE) today announced that its Board of Directors has unanimously decided to appoint Antoine Jouteau as CEO, effective 15 August 2022. Antoine is currently CEO of Adevinta’s leading French marketplace business, leboncoin, and a member of Adevinta’s Executive Leadership team. His appointment follows a comprehensive selection process that considered both internal and external candidates. Antoine will succeed Rolv Erik Ryssdal, who, in February 2022, announced his intention to retire.


Antoine is a proven leader with a deep understanding of the global marketplaces industry, and an impressive track record of successfully building and scaling local brands. By continuously reinventing and diversifying leboncoin, he has built one of the most visited websites in France, with over 29 million monthly users, and more than doubled revenues and profit during his tenure as CEO,” commented Orla Noonan, Adevinta’s Board Chair. “Antoine is uniquely positioned to accelerate Adevinta’s growth ambitions, given his ability to lead, innovate and execute during a period of rapid consumer change, industry disruption and technological advancement. We are confident that Antoine’s product background and relentless focus on the customer experience makes him the ideal new leader for Adevinta.


I am excited by the challenge of leading our continued growth, and creating long-term value for our shareholders, users, business customers, employees and future talent,” said Antoine Jouteau. “With our focus on creating and leveraging innovative technology and capabilities across the group, we are reinventing the way people consume goods and services, by building transactional marketplaces for all generations. I would like to thank the Board for their trust and know that I can rely on the support of all Adevintans, united in our commitment to accelerate the development of the circular economy.

Antoine joined leboncoin in 2009 as its fifth employee, initially as Director of Business Development, progressing to CEO in 2015. Antoine began his career at TDF, an operator of broadcast and telecom infrastructure networks, after which he spent more than seven years developing the digital business of PagesJaunes, the French Yellow Pages. 

Rolv Erik Ryssdal will remain as CEO until 14 August 2022 and will work closely with Antoine to ensure a smooth transition.

Under Rolv Erik’s leadership, Adevinta has become the world’s leading classifieds business, successfully spinning off Adevinta from Schibsted and leading the acquisition of eBay Classifieds Group,” added Orla Noonan. “I speak on behalf of the entire Board when I express my gratitude for his years of service and wish him all the best for the future.

-end- 

Notes to Editors

Media contacts
Mélodie Laroche
Corporate Communications
T: +33 (0) 6 84 30 52 76
melodie.laroche@adevinta.com

Edelman Smithfield
John Kiely / Latika Shah / Olivia Adebo 
John Kiely/ Latika Shah/ Olivia Adebo
T: +44 (0)7785 275665 / +44 (0)7950 671 948 / +44 (0)7787 284 441  
adevinta@edelman.com

About Adevinta

Adevinta is a leading online classifieds specialist, operating digital marketplaces in 14 countries. The company provides technology-based services to connect buyers with sellers and to facilitate transactions, from real estate to motors, and consumer goods.

Adevinta’s portfolio spans more than 40 digital brands, covering one billion people and attracting approximately three billion average monthly visits. Leading brands include top-ranked leboncoin in France, Germany's leading classifieds sites mobile.de and eBay Kleinanzeigen, Marktplaats in the Netherlands, fotocasa and InfoJobs in Spain, Subito in Italy, and 50% of fast-growing OLX Brasil. Adevinta employs around 8,100 people committed to supporting users and customers daily. Find out more at Adevinta.com.

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Tenaris Announces 2024 First Quarter Results25.4.2024 22:30:25 CEST | Press release

The financial and operational information contained in this press release is based on unaudited consolidated condensed interim financial statements presented in U.S. dollars and prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standard Board and adopted by the European Union, or IFRS. Additionally, this press release includes non-IFRS alternative performance measures i.e., EBITDA, Net cash / debt, Free Cash Flow and Operating working capital days. See exhibit I for more details on these alternative performance measures. LUXEMBOURG, April 25, 2024 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) (“Tenaris”) today announced its results for the quarter ended March 31, 2024 in comparison with its results for the quarter ended March 31, 2023. Summary of 2024 First Quarter Results (Comparison with fourth and first quarter of 2023) 1Q 20244Q 20231Q 2023Net sales ($ million)3,4423,4151%4,141(17%)Operating

Combined General Meeting of May 16, 202425.4.2024 22:30:00 CEST | Press release

Châtillon, France, April 25, 2024 Combined General Meeting of May 16, 2024 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), will hold its Combined General Meeting (the “General Meeting”) on May 16, 2024, at 10:00 a.m. CET at the Company’s new headquarters located at IRO Building, 107 Avenue de la République, 92320 Châtillon, France. The preliminary notice (avis de réunion) containing the detailed agenda, draft resolutions as well as instructions to participate and vote for this General Meeting was published in the French “Bulletin des Annonces Légales Obligatoires (BALO)” dated April 8, 2024 (No. 2400716). The meeting notice (avis de convocation) will be published in the BALO and in t

Millicom (Tigo) Board of Directors Appoints Marcelo Benitez as CEO25.4.2024 22:30:00 CEST | Press release

Millicom (Tigo) Board of Directors Appoints Marcelo Benitez as CEO Luxembourg, April 25, 2024 – Millicom announced today that its Board of Directors has appointed Marcelo Benitez as CEO of Millicom, effective June 1, 2024. Benitez has had a distinguished career with Millicom, having joined the company in Paraguay nearly 30 years ago and risen through the Company’s ranks to his most recent role as CEO of TIGO Panama. Benitez's selection completes the final phase of a succession planning and selection process, which included a thorough evaluation of internal and external candidates to ensure that the company's next CEO possesses the vision, experience, talent and leadership qualities necessary to deliver on Millicom's strategic plans. "After an extensive evaluation, it is clear to our Board that Marcelo is the right person to lead Millicom into the future”, indicated Mauricio Ramos, Chair of the Board of Directors of the Company. Under Marcelo’s leadership, TIGO Panama completed the succ

Mohawk Industries Reports Q1 Results25.4.2024 22:10:00 CEST | Press release

CALHOUN, Ga., April 25, 2024 (GLOBE NEWSWIRE) -- Mohawk Industries, Inc. (NYSE: MHK) today announced first quarter 2024 net earnings of $105 million and earnings per share (“EPS”) of $1.64; adjusted net earnings were $119 million, and adjusted EPS was $1.86. Net sales for the first quarter of 2024 were $2.7 billion, a decrease of 4.5% as reported and 5.5% on a legacy and constant basis versus the prior year. During the first quarter of 2023, the Company reported net sales of $2.8 billion, net earnings of $80 million and EPS of $1.26; adjusted net earnings were $112 million, and adjusted EPS was $1.75. Commenting on the Company’s first quarter results, Chairman and CEO Jeff Lorberbaum stated, “Though economic headwinds are impacting industry sales, margins and mix, our first quarter results reflected the positive effect of actions we are taking to enhance our performance. Our earnings per share rose year over year as a result of restructuring, productivity initiatives and benefits from

Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®25.4.2024 22:05:00 CEST | Press release

CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA® CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for TOFIDENCE™ (tocilizumab), a biosimilar monoclonal antibody referencing ROACTEMRA®1. The intravenous formulation of TOFIDENCE has been recommended for approval for the treatment of moderate to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis and COVID-19. The CHMP’s positive opinion will now be referred to the European Commission (EC), which will decide whether to grant marketing authorization for TOFIDENCE. If a marketing authorization is granted by the EC, TOFIDENCE will be an addition to the existing biosimilars portfolio of three widely p

HiddenA line styled icon from Orion Icon Library.Eye